BioRestorative Therapies Inc. Common Stock (NV) (BRTX)

About BRTX

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone…

Sector

Health Care

Industry

Managed Health Care

Employees

13

Website

www.biorestorative.com/

Fundamentals

1-day range

$0.1965$0.219

Market cap

$5.04M

P/E (trailing)

—

P/E (forward)

-0.38

EPS (trailing)

$-1.09

Dividend yield

—

Beta

0.80

Avg. volume

639.5K

Forecasts

2 analyst ratings

BioRestorative Therapies Inc. Common Stock (NV) Competitors

Chosen by industry and closest market cap.

• BRTX

  BioRestorative Therapies Inc. Common Stock (NV)

  $0.199

  ▼ 3.40%
  Market cap $5.04MP/E —
  $0.1593$1.89
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $5.09MP/E —
  $3.18$71.5
• APVO

  Aptevo Therapeutics Inc. Common Stock

  $2.36

  ▼ 2.48%
  Market cap $4.92MP/E 0.00
  $2.3$48.78
• NDRA

  ENDRA Life Sciences Inc. Common Stock

  $5.16

  ▼ 4.63%
  Market cap $5.19MP/E —
  $2.96$9.85
• AIDX

  20/20 Biolabs Inc. Common Stock

  $0.6598

  ▲ 6.42%
  Market cap $5.22MP/E —
  $0.4011$50
• CDIO

  Cardio Diagnostics Holdings Inc. Common stock

  $1.84

  ▼ 1.60%
  Market cap $4.85MP/E —
  $0.97$7.91
• LABT

  Lakewood-Amedex Biotherapeutics Inc. Common Stock

  $2.3

  ▼ 4.56%
  Market cap $5.28MP/E —
  $0.366$9.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not Made Decision To Discontinue Suspended Product Lines
  benzinga · 8/14/2026
• Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not Made Decision To Discontinue Suspended Product Lines
  Benzinga · 8/14/2026
• 12 Health Care Stocks Moving In Friday's After-Market Session
  Benzinga · 8/7/2026
• Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
  Yahoo · 8/6/2026
• 12 Health Care Stocks Moving In Friday's Pre-Market Session
  Benzinga · 7/31/2026

Institutional Ownership

March 31, 2026

Total shares held

637.6K

Total value held

$173.5K

Institutional holders

10